Glivita Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-12-2024
- Paid Up Capital ₹ 0.50 M
as on 16-12-2024
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.82 Cr
as on 16-12-2024
- Revenue 31.03%
(FY 2022)
- Profit 88.95%
(FY 2022)
- Ebitda 185.49%
(FY 2022)
- Net Worth -4.79%
(FY 2022)
- Total Assets 63.32%
(FY 2022)
About Glivita Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹7.82 Cr.
Sampath Gudala, Krishna Gudala, Renuka Gudala, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74999TG2018PTC121737
- Company No.
121737
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jan 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Glivita Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sampath Gudala  | Director | 09-Jan-2018 | Current |
| Krishna Gudala | Director | 09-Jan-2018 | Current |
| Renuka Gudala | Director | 09-Jan-2018 | Current |
| Amarnath Gudala | Director | 09-Jan-2018 | Current |
| Arun Gudala | Director | 09-Jan-2018 | Current |
Financial Performance of Glivita Pharma.
Glivita Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 31.03% increase. The company also saw a substantial improvement in profitability, with a 88.95% increase in profit. The company's net worth dipped by a decrease of 4.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glivita Pharma?
In 2020, Glivita Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sai Pharma Distributors Private LimitedActive 24 years 8 monthsSampath Gudala, Krishna Gudala and 3 more are mutual person
- Spd Vaccines And Speciality Drugs Private LimitedActive 4 years 9 months
Sampath Gudala and Krishna Gudala are mutual person
- Meds N More Healthcare Private LimitedActive 3 years 9 months
Krishna Gudala and Arun Gudala are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Nov 2019 | ₹7.07 Cr | Open |
Others Creation Date: 21 Dec 2018 | ₹7.50 M | Open |
How Many Employees Work at Glivita Pharma?
Unlock and access historical data on people associated with Glivita Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glivita Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glivita Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
